⌘K
t
Genedrive plc announced on October 11, 2021, an amendment to a previous notification, stating that Chairman Dr. Ian Gilham subscribed for 111,121 Open Offer Shares at 25p each on September 28, 2021, instead of 80,000 shares, due to an administrative error. Consequently, Dr. Gilham now holds a total of 614,295 Ordinary Shares, representing 0.67% of the Company's issued share capital.
| Date | 11 Oct 2021 |
| Time | 07:00:10 |
| Category | Director/PDMR dealings |
| ID | 5776O |
genedrive plc
("genedrive", the "Group" or the "Company")
Director's Shareholding
London, UK - 11 October 2021: genedrive plc (LSE: GDR), the near patient molecular diagnostics company has been advised that as a result of an administrative error Dr. Ian Gilham, the Company's chairman, subscribed for 111,121 Open Offer Shares rather than 80,000 Open Offer Shares as was previously announced on 29 September 2021. As a result, Dr. Ian Gilham holds 614,295 Ordinary Shares in the Company, representing 0.67% of the Company's issued share capital. A corrected version of the PDMR notification form originally issued on 29 September 2021 is set out below, the only material change is to the number of Open Offer Shares subscribed for by Dr. Ian Gilham.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 10 September 2021.
For further information, please contact:
|
genedrive plc |
+44 (0) 161 989 0245 |
|
|
David Budd (Chief Executive Officer) Matthew Fowler (Chief Financial Officer) |
|
|
|
|
|
|
|
Peel Hunt LLP - Nominated Adviser & Joint Broker |
+44 (0) 20 7148 8900 |
|
|
James Steel (Investment Banking) |
|
|
|
|
|
|
|
|
|
|
|
finnCap Ltd - Joint Broker |
+44 (0) 20 7220 0500 |
|
|
Geoff Nash / Kate Bannatyne (Corporate Finance) |
|
|
|
|
|
|
|
|
|
|
|
Walbrook PR - Financial PR & IR Adviser |
+44 (0) 20 7933 8780 |
|
|
Paul McManus / Anna Dunphy |
|
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||
|
a. |
Name |
1. David Budd 2. Matthew Fowler 3. Dr. Ian Gilham 4. Tom Lindsay 5. Chris Yates |
||
|
2. |
Reason for the notification |
|||
|
a. |
Position/status |
1. Chief Executive Officer 2. Chief Financial Officer 3. Non-Executive Chairman 4. Non-Executive Director 5. Non-Executive Director |
||
|
b. |
Initial notification /Amendment |
Amendment |
||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||
|
a. |
Name |
genedrive plc |
||
|
b. |
LEI |
213800ZYODIRZ87Y4K14 |
||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Ordinary Shares of 1.5p each
GB00B1VKB244 |
||
|
b. |
Nature of the transaction |
Purchase of new ordinary shares pursuant to an open offer which remains subject to Admission and other conditions
|
||
|
c. |
Price(s) and volume(s) |
|
||
|
d. |
Aggregated information ·Aggregated volume ·Price
|
N/A
|
||
|
e. |
Date of the transaction |
28 September 2021 |
||
|
f. |
Place of the transaction |
London |
||
About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV and certain military biological targets. The Company released a high throughput SARS-CoV-2 assay in 2020, and has a point of care version of the SARS-Cov-2 test in development. Antibiotic Induced Hearing Loss represents the Company's first targeting of the Genedrive® system into an emergency/urgent care environment.